Increasing percentages of CR and MRD- CR after first-line treatment in CLL patients. The results presented are after the administration of: chlorambucil; fludarabine (for which only clinical responses are shown); alemtuzumab; the FC combination5; FCR; FCM; RFCM (for which MRD- cases as assessed by high-sensitivity methods are shown). Percentages of MRD+ cases or those without MRD evaluation are depicted in blue; MRD- cases are in green.